What Selenase Treats: Main Uses and Benefits

Selenase is primarily used to address a proven, quantifiable deficiency of Selenium, an essential trace element. It is applied in clinical settings for the treatment of proven selenium deficiency that cannot be compensated by nutrition alone. The medication is commonly used across conditions presenting with acute episodes of depletion, such as in patients facing severe sepsis or septic shock, and in chronic scenarios like malabsorption syndromes or long-term Total Parenteral Nutrition (TPN). It is also applied in addressing specific deficiency-driven conditions like Keshan disease and Kashin-Beck disease.

The therapeutic benefit supports the body's elemental balance for systemic function, which in turn may assist with general well-being during symptomatic phases. Quick Fact: Relief for Persistent Fatigue. This helps manage symptom clusters arising from a chronic lack of the element, including generalized muscle weakness and hair/nail abnormalities.

“Providing support for the body’s elemental requirements is relevant for easing symptoms during nutritional imbalances.”

It provides supportive relief that contributes to easing the overall symptom load associated with these manifestations.

Regulatory References

1. (HPRA Summary of Product Characteristics)

Selenase (Sodium Selenite) is regulated for use only when a proven, quantifiable selenium deficiency exists that cannot be corrected by nutritional means. This confirmed deficiency is the fundamental eligibility requirement for treatment in the general population.

Official Contraindications and Non-Eligibility

Individuals are strictly prohibited from using Selenase if they have:

Classification	Population/Condition	Regulatory Basis
Absolute Contraindication	Known hypersensitivity to Sodium Selenite or its excipients.	SmPC/FDA
Absolute Contraindication	A current state of Selenosis (acute or chronic selenium overdose).	SmPC/FDA

Age-Specific Eligibility and Restrictions

Use is established for adult patients. It is also indicated for pediatric patients, particularly as a source of selenium in parenteral nutrition. However, a caution is noted for preterm infants receiving injectable forms due to an increased risk of aluminum toxicity.

Conditional Use and Data Limitations

The medicine is permitted for use during pregnancy and lactation, provided the woman has a proven deficiency. Regulatory documentation notes a lack of scientific evidence for dosage adjustment in patients with existing renal or hepatic impairment.

Selenase (sodium selenite pentahydrate) has specific, documented interactions primarily based on chemical incompatibility, which can affect its bioavailability.

Documented Interactions

Product Category	Specific Interacting Medicine	Interaction Mechanism	Management and Constraint
Reducing Substances	Vitamin C (Ascorbic Acid)	Chemical reduction of selenium salt to elemental selenium, leading to precipitation.	Do not mix oral solution or injection with reducing substances (e.g., Vitamin C). For oral administration, a 4-hour interval between selenase and Vitamin C is required.

Procedural and Environmental Constraints

The most critical interactions for selenase are procedural and require attention during preparation and administration. The incompatibility with reducing substances means that for both oral and injection solutions, the mixture must not be prepared simultaneously with such substances to prevent the formation of elemental selenium, which has no biological availability. Non-specific precipitation in infusion solutions must also be avoided on safety grounds, which is supported by the requirement that the pH value of prepared solutions must not fall below 7.0. There are no widely documented clinical pharmacokinetic interactions involving the major drug metabolizing enzymes or transporters for selenase.

The mechanism of Sodium Selenite is defined by its function as an elemental precursor, providing the body with the trace element Selenium required to synthesize the essential amino acid Selenocysteine. Selenocysteine is then incorporated into the structure of key enzymes known as Selenoproteins (e.g., Glutathione Peroxidase ( GPx)). The elemental incorporation supports the reversal of impaired enzyme synthesis capacity that results from an elemental deficiency and is a prerequisite for the drug's downstream effects.

---

The synthesized GPx enzyme functions within the body's primary Antioxidant Defense Pathway by rapidly catalyzing the reduction of destructive Reactive Oxygen Species (ROS), such as hydrogen peroxide, into harmless substances. This activity results in the catalytic reduction of ROS and the subsequent moderation of oxidative impact on cellular components, influencing immune and metabolic pathway dynamics.

---

The biological function is strictly dependent on the existence of a Selenium deficiency; the mechanism does not apply where selenium concentrations are sufficient. Furthermore, the resulting re-establishment of antioxidant enzyme function is a gradual process, as it is dictated by the time required for genetic transcription and the de novo synthesis of functional Selenoproteins to complete the synthesis of the systemic enzyme pool.

The administration of Selenase (Sodium Selenite) follows specific parameters defining the routes, dosage, and preparation steps.

Routes, Forms, and Schedule

The medicine is available in formulations for three primary routes: oral administration via solution, and both intravenous (IV) injection or slow infusion, and intramuscular (IM) injection for the parenteral solution. The standard schedule for both nutritional maintenance and short-term deficiency treatment is once daily.

---

Dosage Ranges and Duration

Adult dosing is determined by clinical requirements. For ongoing nutritional maintenance, the dose is typically 60 mug to 100 mug of selenium daily. For the short-term treatment of a confirmed deficiency, the daily amount may reach a maximum of 400 mug. The duration of higher-dose treatment is tied to the monitoring of selenium concentrations in the blood, continuing until laboratory values normalize, while maintenance dosing may be long-term.

---

Contextual Administration Rules

Specific instructions facilitate proper use. The oral solution is held in the mouth for approximately 30 to 60 seconds before swallowing. For the oral form, there is a 4-hour separation between the intake of Selenase and any dose of oral Vitamin C. When the injection solution is administered intravenously, it must first be diluted in an isotonic solution or parenteral nutrition solution. Further constraints for IV preparation include maintaining the pH value above 7.0 and preventing the mixture of the solution with reducing substances to avoid chemical precipitation.

---

Population Use

For pediatric patients, the administration is defined by weight, typically utilizing a mug/kg calculation rather than a fixed standard adult dose. Dose adjustments for patients with renal or hepatic impairment are not specified due to a lack of available data for these populations.

Research evidence / Overview of studies for selenase

Selenase (sodium selenite) was studied for its ability to correct proven low levels of the essential trace element selenium. The body of research includes trials examining the correction of general elemental deficiency and specific studies conducted in critical care settings and highly deficient geographical regions.

---

Evidence for Use in Correcting Proven Deficiency (General)

Research into the main, regulated use of selenase includes various short-term randomized controlled trials (RCTs) and observational studies. These trials were conducted in settings where patients had a documented shortage of selenium, such as individuals receiving specialized intravenous nutrition (TPN) or those with chronic conditions like cirrhosis. Research examined whether sodium selenite administration was associated with measurable increases in selenium concentrations in the blood, and if the activity of Selenoproteins, enzymes that require selenium, was evaluated in these settings.

Studies consistently reported that when selenase was administered, blood levels of selenium and the activity of Selenoproteins was associated with measurable increases and an increase toward baseline or normal range. The consistency of the biomarker data from this evidence base was frequently observed in scientific literature.

Evidence is limited regarding the direct relationship between biomarker changes and sustained, observable changes in chronic deficiency symptoms, such as muscle weakness or nail changes, in general patient groups. Follow-up durations were limited in many of these trials, meaning long-term effects are not fully established beyond the period needed to address the deficiency.

---

Evidence for Use in Severe Sepsis and Septic Shock

The use of selenase in critically ill patients, specifically those with severe sepsis and septic shock, was studied for through numerous RCTs, which often used intravenous administration. Research examined outcomes related to physiological strain or stress, including all-cause mortality at set time points, the duration of stay in the Intensive Care Unit (ICU) and the hospital, and changes in organ failure assessment scores.

Systematic reviews and meta-analyses reported that findings were mixed and evidence quality varies across studies. For the primary measure of 28-day mortality, the overall data show patterns related to inconsistency across trials. Subgroup analyses was observed in some trials, where certain patterns of change were observed in some studies that focused on patients with a particularly severe baseline selenium deficiency.

Key limitations in this research include the high heterogeneity in trial designs, the varying doses of selenite administered, and the fact that certainty remains low for major outcomes like survival. Comparative evidence is lacking to definitively establish clear patterns of response across all critically ill groups.

---

Evidence for Use in Endemic Deficiency Diseases

Specific research was studied for selenium deficiency associated with endemic diseases, notably Keshan disease (a type of heart condition) and Kashin-Beck disease (an osteoarthropathy). This evidence comes mainly from large-scale, long-term intervention trials and epidemiological studies conducted in geographically specific, highly selenium-deficient regions.

These studies monitored the incidence (rate of new cases) and prevalence of these conditions. The research highlights changes measured during the study period, with findings describing a significant reduction in the incidence of Keshan disease in endemic populations that received supplementation.

Results apply only to the populations studied in these specific geographical contexts. Because these diseases are multifactorial, the interplay between selenium and other potential factors, such as mycotoxins, is an area where data are still emerging.

---

Long-Term Studies and Follow-Up Data

Research examined various time intervals to assess the measured changes of selenase. For the general indication, research explores short-term symptom changes and elemental correction, meaning follow-up durations were limited to the acute phase of treatment or the first few weeks following administration.

There is limited information for long-term outcomes regarding the sustained maintenance of corrected selenium levels over many months or years without continued supplementation. Long-term effects are not fully established for patients in the critical care setting, as most studies track outcomes only up to a few months post-hospital discharge. This means data are still emerging regarding the durability of any observed response in these populations.

---

Evidence in Special Populations and Subgroups

The majority of formal studies have focused on the general adult population, particularly in the critical care context. Research was evaluated in subgroups defined by their disease severity or their severe baseline deficiency levels, with some studies showing different patterns in these groups compared to the overall study population.

Data for certain groups remain insufficient. For instance, while endemic disease research involved children and adolescents, broad evidence for the outcomes of selenase administration in children and older adults across diverse conditions is limited. Subgroup findings are uncertain when trying to generalize research findings across different patient groups, such as those with specific concurrent illnesses or different degrees of elemental deficiency.

---

Key Limitations and Research Uncertainty

The evidence base for selenase contributes to understanding symptom patterns related to deficiency, but key limitations have been identified. For the general and critical care indications, the evidence quality varies across studies, and the findings were mixed for major clinical endpoints like mortality.

Research highlights that a key uncertainty lies in generalizing findings across the spectrum of conditions for which deficiency is a factor. Certainty remains low on the optimal regimen needed to achieve clinical outcomes versus simply correcting biomarkers. Research does not determine whether an individual will respond similarly to the group patterns observed, and comparative evidence is lacking in certain subgroups, making it difficult to fully contextualize the observed patterns of change.

Key Studies & References

1. Selenase Oral Solution and Solution for Injection: Summary of Product Characteristics (HPRA)

Common questions about selenase (FAQ)

Q: Can I stop taking selenase once I start feeling better?

According to official product information, treatment for a confirmed selenium deficiency is monitored based on blood selenium concentrations in a laboratory. The duration and continuation of the higher-dose regimen are determined by these laboratory results, not solely by a patient's self-reported change in symptoms.

Q: What should I do if I forget to take my selenase dose?

Official product information typically contains guidance stating that a double dose should not be taken to make up for a missed dose. Patients are directed to follow the specific instructions from their prescribing healthcare professional.

Q: Does taking selenase interfere with common pain relievers like ibuprofen?

Official labeling generally addresses chemical incompatibilities, such as the interaction with Vitamin C. The product information does not specifically document clinical pharmacokinetic interactions with major drug metabolizing enzymes, which are responsible for processing various medicines.

Q: Can I use selenase if I am currently taking medication for a thyroid condition?

Regulatory documents do not explicitly list specific interactions between Selenase and common thyroid medications. It is standard regulatory practice that the prescribing professional must be fully informed of all medicines the patient is currently taking.

Q: Are there any food or drink restrictions while using selenase?

The primary constraint listed in official documentation is related to Vitamin C (ascorbic acid). For the oral solution, the product label requires intake to be separated from any dose of Vitamin C by at least 4 hours. No other general food or drink restrictions are specified in the official labeling.

Q: Does selenase interact with commonly prescribed diabetes medications?

Official product information does not explicitly document specific interactions with commonly prescribed diabetes medications (such as metformin). This information is evaluated by the prescribing professional who manages the patient’s complete medication list.

Q: Does selenase affect how birth control pills work?

Official regulatory sources do not document a specific interaction between Selenase and hormonal contraceptives, such as birth control pills. It is standard practice to discuss all concurrent medicines with a prescribing professional.

Q: Are there any specific lifestyle changes recommended when taking selenase?

The official product label defines the procedural constraint of separating the oral medicine from Vitamin C intake. No other general lifestyle changes, such as dietary modifications or changes to exercise habits, are required by the regulatory label.

Q: Is selenase approved for use in all countries?

Selenase has been approved by numerous large regulatory bodies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). However, regulatory approval is managed on a country-by-country basis, meaning the product is not necessarily registered for use in all countries worldwide.

Q: What kind of specialist typically prescribes selenase?

Official information indicates the product is used to correct trace element deficiency and has been studied in contexts such as critical care and specialized intravenous nutrition. These settings involve professionals experienced in managing mineral and trace element balance.

Q: Does selenase contain lactose or gluten?

The active ingredient, Sodium Selenite, is an inorganic substance and is gluten-free. However, the precise composition of inactive ingredients (excipients) can vary by the specific product form and manufacturer. Patients must verify the full composition on the product label.

Q: Are there any warnings about operating machinery while using selenase?

Official regulatory documents do not list any specific warnings or precautions regarding the effects of using Selenase on a patient's ability to drive a vehicle or operate heavy machinery.

Q: What should I do if a side effect is listed as 'rare'?

Official regulatory documents define 'rare' side effects as those that may be observed in up to 1 in 1,000 people. If an adverse reaction is listed as 'frequency not known', it means the incidence cannot be reliably estimated from the available data.

Q: Does selenase interact with blood pressure medications?

Official product information does not explicitly document specific interactions between Selenase and commonly used blood pressure medications. Providing a complete medication list to the prescribing professional is a standard requirement for starting treatment.

How to Store and Dispose of Selenase (Official Regulatory Information)

Official regulatory guidelines strictly define the necessary conditions for storing and disposing of selenase (sodium selenite pentahydrate) to ensure stability and public safety.

Storage and Handling Requirements

Condition	Requirement
Temperature	Do not store the oral solution above 25 C.
Container Use	Use single-dose containers (ampoules/bottles) immediately after opening; discard any unused contents.
Child Safety	Keep this medicine out of the sight and reach of children.
Admixtures	Compounded solutions (e.g., in PN) may require refrigeration and light protection, with infusion completed within 24 hours.

Disposal Instructions

Disposal must be managed according to environmental protection rules. Do not dispose of unused or expired selenase in household waste or by pouring it down a drain. To properly dispose of the medicine, return it to a pharmacist for processing via appropriate pharmaceutical take-back programs.